Late-Breaking Research: Experimental and Molecular Therapeutics 2

• LB180 Isocitrate dehydrogenase (IDH) isoform switch confers resistance to ivosidenib in myelodysplastic neoplasm Nicole Lux, Patrick R. Gonzales, Stephen D. Hyter, Shivani Golem, Wei Cui, Ramesh Balusu, Abdulraheem Yacoub
• LB182 CTC/cfDNA biomarker-guided precision medicine to overcome immune checkpoint inhibitor resistance in hepatocellular carcinoma Yang Cui, Alexandria Borges, Meng Li, Linda Sher, Bangyan Stiles, Dan G. Duda, Anthony El-Khoueiry, Keigo Machida
• LB183 Strong durable tumor regressions with the KRAS G12D ON/OFF inhibitor VS-7375 in combination with PRMT5 inhibition in MTAP-deleted/KRAS G12D -mutant pancreatic cancer Ryan D. Mouery, Kristina Drizyte-Miller, Clint A. Stalnecker, Adrienne D. Cox, Silvia Coma, Jonathan A. Pachter, Channing J. Der
• LB184 · PDF Mechanisms of acquired resistance following dual EGFR/MET inhibition in MET-amplified EGFR TKI-resistant lung cancer Yen-Ting Lin, Yi-Nan Liu, Ya-Chieh Hsu, You-Chia Hsu, Shang-Gin Wu, Tzu-Hsiu Tsai, Wei-Yu Liao, Chao-Chi Ho, Jin-Yuan Shih
• LB185 Novel peptide decoy targeting mitochondrial dihydrolipoyl transacetylase-driven redox signaling to improve cancer chemotherapy outcomes Jung Seok Hwang, Jaehyun Kim, Kiyoung Eun, Vanessa Avalos, Sydney Shuff, Margaret Stephens, Sumin Kang
• LB186 Oncogenic KRAS mutations drive estrogen independence and induce targetable vulnerabilities in treatment-resistant ER+ breast cancer Priya S. Hibshman, Dan Ye, Rosario Chica-Parrado, Saurabh Mendiratta, Albert Lin, Ariella B. Hanker, Carlos L. Arteaga
• LB187 KRAS-MAPK signaling adaptation underlies acquired resistance to wild-type IDH1 inhibition in pancreatic ductal adenocarcinoma Sami O. Abul-Khoudoud, Mehrdad Zarei, Priyashree Sunita, Goutam Dey, Semmer Ali, Faith Nakazzi, Hallie J. Graor, Jordan M. Winter
• LB188 Mutagenesis-driven genome instability links ecDNA amplification to drug resistance and immune modulation in prostate cancer Xiaoling Li
• LB189 Therapeutic Targeting of Spliceosomal Proteins hnRNPH1/H2 Demonstrates Potent Anti-Melanoma Activity In BRAF Inhibitor Resistant Melanoma, and Enhances Tumor Immune Response Sadeeshkumar Velayutham, Maab Sultan, Tulsi Desai, Shweta Shah, Nhut Minh Nguyen, Eli Rome, Ryan Seerattan, Aveta Singh, Keiran Smalley, Jun Yong Choi, Vladimir Beljanski, Dmitriy Minond
• LB190 Single cell DNA sequencing reveals clonal selection, hormonal adaptation and treatment resistance in neoadjuvant clinical trial of Aromatase inhibition Vessela N. Kristensen, Denise G. O`Mahony, Tom Lesluyes, Ina S. Brorson, Patrik H. Vernhoff, Ksenia Sokolova, Miriam R. Aure, Grethe G. Alnæs, Rebecca M. Hoøen, Arvind Y. M. Sundaram, Chandra Theesfeld, Stephanie B. Geisler, Torill Sauer Sauer, Nazli Bahrami, Andliena Tahiri, Torben Lüders, Olga Troyanskaya, Charles Vaske, Peter Van Loo, Jürgen Geisler
• LB191 · PDF Decoding metastasis and therapy resistance in sarcomatoid bladder cancer Jiaqian Luo, Sizhi P. Gao, Jacob E. Tallman, Fengshen Kuo, Merve Basar, Cansu Yol, Syed M. Alam, Hui Jiang, Xinran Tang, Alejandra Lopez Rojas, Ecenur Turkay, Jonathan E. Rosenberg, Iyer Gopakumar, Eugene J. Pietzak, David B. Solit, Hikmat Al-Ahmadie
• LB194 · PDF SIRT5 induces a metabolic switch to fuel nucleotide pools and chemoresistance in triple-negative breast cancer Zuen Ren, Tiziano Bernasocchi, Kiran Kurmi, Chenxu（Vincent） Guo, Kevin Jiang, Eric Zaniewski, Garrett Lam, Kazi N. Islam, Shakchhi Joshi, Xin Li, Ilze Smidt, Agustina Maccio, Robert Morris, Bryce Ordway, Veerle I. Bossuyt, Gary X. Wang, Shinn-Huey S. Chou, Lee Zou, Ioannis Sanidas, Laura M. Spring, Michael Lawrence, Esther Rheinbay, Wilhelm Haas, Raul Mostoslavsky, Marcia C. Haigis, Leif W. Ellisen
• LB196 · PDF Fluorinated cuban-1-yl biguanides overcome hormone therapy resistance to standard of care fulvestrant, and palbociclib Zhijun Guo, Jianxun Lei, Christian T. Wells, Allison M. Makovec, Andrew C. Yates, Swaathi Jayaraman, John R. Hawse, Joshua A. McCarra, Qing Cao, Michael J. Pryzbilla, Brenda L. Koniar, Beverly J. Norris, Craig M. Florey, Robert J. Schumacher, Michael A. Farrar, Kaylee L. Schwertfeger, Elizabeth A. Ambrose, Henry Wong, Gunda I. Georg, Antonino D'Assoro, Matthew P. Goetz, David A. Potter
• LB197 VS-7375, a non-covalent dual ON/OFF KRAS G12D inhibitor, displays superior activity to ON-only KRAS G12D inhibitors in preclinical models of pancreatic cancer Brandon L. Mouery, Clint A. Stalnecker, Adrienne D. Cox, Silvia Coma, Jonathan A. Pachter, Channing J. Der
• LB198 · PDF Targeting galectin-1 overcomes paclitaxel resistance in esophageal squamous cell carcinoma Xiang Li
• LB199 High-plex spatial transcriptomics reveals triplatin-induced DNA damage signaling and tumor-fibroblast niche reprogramming in pancreatic cancer PDX models Praveen Bhoopathi, Khoa L. A. Huynh, Erica J. Peterson, Vashti Bandy, Anna Gibson, Vignesh Vudatha, Arunima Punjala, Dongyu Zhang, Jinze Liu, J Chuck Harrell, Nicholas P. Farrell, Jose G. Trevino
• LB475 GPER as an actionable target in endocrine resistant breast cancer Sierra Vidaurri, Shweta Singh, Valerie Ledezma, Emma Garza, Francisco Flores, Alexander Lim, Muhammad Noorani, Shubhank Goyal, Aura Calderon, Anupam Dhasmana, Swati Dhasmana, Murali Mohan Yallapu, Subhash C. Chauhan, Diane Nguyen, Sheema Khan

在完整检索应用中浏览本分会场 →